Dr. Nick Vitanza is a pediatric neuro-oncologist at Seattle Children’s Hospital and laboratory researcher at the Fred Hutchinson Cancer Research Center. He completed a pediatric oncology fellowship at New York University, during which he studied molecular avenues of chemotherapy resistance in the Bill Carroll Lab and received an ASPHO Young Investigator travel award. He went on to complete a pediatric neuro-oncology fellowship at Stanford University and a post-doctoral fellowship in the Michelle Monje Lab where he led work published in Cancer Cell that defined transcriptional dependencies of Diffuse Intrinsic Pontine Glioma (DIPG)/Diffuse Midline Glioma (DMG) and evaluated combinatorial treatment strategies. In 2016, Dr. Vitanza joined the faculty at Seattle Children’s Hospital where he is an Assistant Professor of Pediatrics and treats children with brain and spinal cord tumors. Nick is also an Investigator at the Seattle Children’s Research Institute, where he is the CNS Immunotherapy Lead and the Principal Investigator of BrainChild-01, a first-in-human clinical trial evaluating locoregional CAR T cells for children with recurrent or refractory HER2-positive CNS tumors. Under the mentorship of Jim Olson, Nick is a Principal Investigator at the Fred Hutchinson Cancer Research Center, leading the DIPG/DMG group with a focus on using treatment-naïve biopsy-derived in vivo models to better understand the innate biology and treatment-responses of these tumors. His research is generously funded by a Defeat DIPG ChadTough Research Grant, the McKenna Claire Foundation, the Pediatric Brain Tumor Research Fund, and Unravel Pediatric Cancer.